• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

bioLIVE to Introduce Global Biopharma Country Ranking



 -UBM’s bioprocessing and manufacturing event opening in October (9-11) in Madrid, Spain - has announced that it is to build on the success of last year’s global small molecule country rankings by introducing a biologics manufacturing and processing league table, which will rank the perception of the world’s largest biologics markets for “overall quality”, “growth potential” [for exports and domestic market], “innovation” and “ability to meet future capacity constraints”.   The study will evaluate the consequences for the supply chainwhich markets are seen to have the best potential growth both domestically and for exports. Last year’s small molecule ranking demonstrated that the traditional economies of the USA, Germany and Japan were still perceived as the strongest, but newer bio regions such as Korea, China, and Singapore are ranking much higher for large molecule manufacturing. Additionally, the research will also evaluate what the potentially geopolitical and supply chain risk is in newer regions, as well as the knowledge of bio professionals.    Rutger Oudejans, Brand Director at UBM for bioLIVE, commented: “Biologics capacity is growing quickly and will increase by nearly 40% over the next four years. Asia and European countries are building more facilities, which is reducing the USA’s overall market share of capacity. What no one has yet evaluated is the relative perceived strengths of each region. The perception of each country will undoubtedly be a factor in realizing its growth potential.   “One of the great successes of the small molecules space has been the internationalization of the supply chain, and we want to bring this experience and couple it with industry analysis from prominent experts, and new original research, so that we can better inform the bio community on the opportunities available.”

Related Videos
Related Content